Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease. The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.
Round one provided support to Denteric, an early-stage biotech developing therapies targeting Porphyromonas gingivalis (Pg) related diseases – initially focused on severe periodontal disease.
Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.
Denteric co-founder Professor Reynolds has been recognised for his outstanding achievement in translating scientific discoveries into globally successful products that prevent and treat oral disease.
CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.
A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.